Elevance Health, Inc. (NYSE:ELV - Free Report) - Research analysts at Zacks Research boosted their Q2 2025 earnings estimates for Elevance Health in a research report issued on Wednesday, December 18th. Zacks Research analyst K. Dey now expects that the company will post earnings per share of $10.35 for the quarter, up from their previous estimate of $10.22. The consensus estimate for Elevance Health's current full-year earnings is $32.96 per share. Zacks Research also issued estimates for Elevance Health's Q4 2025 earnings at $4.68 EPS, Q2 2026 earnings at $11.90 EPS, Q3 2026 earnings at $10.65 EPS and FY2026 earnings at $40.48 EPS.
Elevance Health (NYSE:ELV - Get Free Report) last posted its earnings results on Thursday, October 17th. The company reported $8.37 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $9.66 by ($1.29). The firm had revenue of $44.72 billion during the quarter, compared to the consensus estimate of $43.47 billion. Elevance Health had a net margin of 3.68% and a return on equity of 19.56%. The business's revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the firm posted $8.99 EPS.
A number of other equities research analysts have also recently commented on ELV. StockNews.com cut Elevance Health from a "buy" rating to a "hold" rating in a research note on Wednesday, December 18th. Royal Bank of Canada cut their price target on shares of Elevance Health from $585.00 to $478.00 and set an "outperform" rating on the stock in a research report on Friday, October 18th. Cantor Fitzgerald decreased their price objective on shares of Elevance Health from $600.00 to $485.00 and set an "overweight" rating for the company in a report on Friday, October 18th. Barclays lowered their target price on shares of Elevance Health from $622.00 to $501.00 and set an "overweight" rating for the company in a research note on Tuesday, October 22nd. Finally, Stephens reissued an "underperform" rating on shares of Elevance Health in a report on Friday, October 18th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $539.20.
Read Our Latest Report on Elevance Health
Elevance Health stock opened at $365.96 on Monday. The business's 50-day simple moving average is $409.70 and its 200 day simple moving average is $488.69. The company has a quick ratio of 1.50, a current ratio of 1.50 and a debt-to-equity ratio of 0.56. The stock has a market cap of $84.87 billion, a price-to-earnings ratio of 13.34, a P/E/G ratio of 1.15 and a beta of 0.83. Elevance Health has a 12-month low of $362.21 and a 12-month high of $567.26.
The business also recently disclosed a quarterly dividend, which was paid on Friday, December 20th. Shareholders of record on Thursday, December 5th were given a dividend of $1.63 per share. The ex-dividend date was Thursday, December 5th. This represents a $6.52 dividend on an annualized basis and a yield of 1.78%. Elevance Health's dividend payout ratio (DPR) is 23.77%.
In related news, EVP Charles Morgan Kendrick, Jr. sold 7,417 shares of the stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $432.14, for a total transaction of $3,205,182.38. Following the sale, the executive vice president now owns 8,423 shares of the company's stock, valued at $3,639,915.22. This represents a 46.82 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 0.35% of the company's stock.
A number of hedge funds have recently added to or reduced their stakes in the company. Cambridge Investment Research Advisors Inc. lifted its stake in shares of Elevance Health by 16.4% in the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 32,467 shares of the company's stock valued at $17,592,000 after acquiring an additional 4,566 shares during the last quarter. Atomi Financial Group Inc. grew its holdings in Elevance Health by 7.9% during the 2nd quarter. Atomi Financial Group Inc. now owns 590 shares of the company's stock worth $320,000 after acquiring an additional 43 shares during the last quarter. AustralianSuper Pty Ltd increased its position in Elevance Health by 14.8% in the 2nd quarter. AustralianSuper Pty Ltd now owns 7,898 shares of the company's stock valued at $4,280,000 after acquiring an additional 1,016 shares during the period. Patriot Financial Group Insurance Agency LLC lifted its holdings in shares of Elevance Health by 12.8% during the second quarter. Patriot Financial Group Insurance Agency LLC now owns 4,012 shares of the company's stock worth $2,174,000 after purchasing an additional 456 shares during the period. Finally, LS Investment Advisors LLC grew its stake in shares of Elevance Health by 19.3% in the second quarter. LS Investment Advisors LLC now owns 5,774 shares of the company's stock worth $3,129,000 after purchasing an additional 933 shares during the last quarter. 89.24% of the stock is owned by institutional investors.
Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Elevance Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elevance Health wasn't on the list.
While Elevance Health currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.